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Intravenous delivery of adeno-associated virus 9-encoded
IGF-1Ea propeptide improves post-infarct cardiac remodelling
Enrique Gallego-Colon1, Maria Villalba2, Joanne Tonkin1, Francisco Cruz2, Juan Antonio Bernal2, Luis J Jimenez-Borregureo2,
Michael D Schneider1, Enrique Lara-Pezzi1,2 and Nadia Rosenthal1,3
The insulin-like growth factor Ea propeptide (IGF-1Ea) is a powerful enhancer of cardiac muscle growth and regeneration, also
blocking age-related atrophy and beneﬁcial in multiple skeletal muscle diseases. The therapeutic potential of IGF-1Ea compared
with mature IGF-1 derives from its local action in the area of synthesis. We have developed an adeno-associated virus (AAV) vector
for IGF-1Ea delivery to the heart to treat mice after myocardial infarction and examine the reparative effects of local IGF-1Ea
production on left ventricular remodelling. A cardiotropic AAV9 vector carrying a cardiomyocyte-speciﬁc IGF-1Ea-luciferase
bi-cistronic gene expression cassette (AAV9.IGF-1Ea) was administered intravenously to infarcted mice, 5 h after ischemia followed
by reperfusion (I/R), as a model of myocardial infarction. Virally encoded IGF-1Ea in the heart improved global left ventricular
function and remodelling, as measured by wall motion and thickness, 28 days after delivery, with higher viral titers yielding better
improvement. The present study demonstrates that single intravenous AAV9-mediated IGF-1Ea Gene Therapy represents a tissue-
targeted therapeutic approach to prevent the adverse remodelling after myocardial infarct.
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INTRODUCTION
Cardiovascular diseases (CVD) are mainly disorders of the blood
vessels and the heart, and are the number one cause of death
globally.1 Among the most common types of CVD, ischemic injury
leading to left ventricular (LV) dysfunction is a major cause of
mortality.2,3 Current interventions4 for ischemic injury are targeted
at physical removal of the obstructions of the heart vessels to
restore blood ﬂow to ischemic tissue. Paradoxically, reperfusion of
the tissue leads to increased radical oxygen species production,
which potentially causes adverse effects on the surviving
myocardium.5 Over the past decades, treatment for myocardial
ischemia has made signiﬁcant progress; unfortunately, myocardial
infarction remains an unsolved therapeutic target.
Insulin-like growth factor-1 (IGF-1),6 an FDA-approved treatment
for short-stature in children, has been extensively tested for its
therapeutic properties in the resolution of tissue injury.7 In adults,
serum IGF-1 is mainly secreted by the liver and functions as an
endocrine mediator of growth and metabolism.8 IGF-1 is also
transiently produced upon injury on most cell types to act locally
in an autocrine and paracrine manner where it regulates cellular
survival, proliferation and differentiation, but the molecular basis
of these diverse functions is not well understood.9 Using mouse
transgenesis supplemental expression of a locally acting IGF-1 Ea
propeptide (IGF-1Ea) promoted efﬁcient tissue repair of skeletal
muscle without scar tissue formation by increasing ﬁbre size and
muscle size hypertrophy, reducing cachexia, ageing, increasing
the number of myogenic progenitors and promoting the fusion of
nascent myocytes.10–12 Furthermore, it has been demonstrated
that IGF-1 accelerates muscle regeneration by modulating
inﬂammatory cytokines and macrophage polarisation during
muscle regeneration.13,14 In the heart, transgenic IGF-1Ea restored
heart functionality post-infarct, increasing anti-apoptotic signal-
ling and reducing scar formation facilitated by the modulation of
the innate immune cell populations soon after infarction,
favouring a reduction in inﬂammatory myeloid cells, modulating
cytokine expression and matrix turnover within the ﬁrst 7 days
after infarct.15,16 These studies suggest how supplemental IGF-1Ea,
expressed locally, can modulate the stimulus of injury or disease,
by mobilising immune cells to target and rebuild damaged tissues
in a new paradigm of self-renewal. However, the heart-speciﬁc
transgene is expressed from the time of cardiac myogenesis
onward, and does not simulate delivery to humans in the clinic.
In the present study, we tested adeno-associated virus (AAV)-9
as a therapeutically relevant vector for promoting heart repair
with IGF-1Ea. In recent years, the use of AAV has proved to be the
most promising gene delivery system for the transfer of genes to
post-mitotic cells in vitro and in vivo.17–19 So far, high efﬁciency
whole-heart gene delivery in small animals has only been
effectively achieved with AAV serotype 9.20,21 We therefore
exploited intravenous delivery of an AAV9-based IGF-1Ea gene
vector to ameliorate the adverse effects of the heart remodelling
after ischemic injury, as a clinically applicable delivery system.
RESULTS
Characteristics of intravenous AAV9.IGF-1Ea gene transfer
To evaluate the therapeutic potential of AAV9-mediated IGF-1Ea
gene transfer, we constructed an AAV9 vector encoding the
IGF-1Ea mouse complementary DNA (cDNA), the expression of
which was driven by the cardiac troponin promoter (cTNT). The
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plasmid also contained an internal ribosomal entry site for the
luciferase gene (Figure 1a), allowing gene delivery to be readily
assayed. We ﬁrst assessed transduction levels by administering
3.5 × 1011 GC of AAV9.IGF-1Ea in a single intra-femoral vein
injection to C57BL/6 mice. The in vivo expression of luciferase was
evaluated at different time points. Signiﬁcant expression of
luciferase in vivo was seen in the heart at 7 days post-injection.
Ectopic expression in the liver was detected albeit at much lower
levels than in the heart, as early as 2 days post-injection
(Figure 1b), temporarily overriding the speciﬁcity of the cTNT
promoter. Ex vivo imaging detected luciferase expression in the
heart as early as 3 days post-injection (Figure 1c and
Supplementary Figure S1A,B). Further analysis revealed that the
emission of photons at 3 days may be blocked by the tissue
thickness and composition of the chest (Supplementary
Figure S1C). Quantitative analysis of luciferase and IGF-1Ea
expression veriﬁed increased levels of messenger RNA (mRNA)
by 3 days post-injection, however, IGF-1Ea levels were not
signiﬁcantly induced until 7 days post-injection (Figure 1c,d). By
contrast, there was no difference in IGF-1Ea expression between
control and AAV9.IGF-1Ea groups in the liver and lung
(Supplementary Figure S2A,B). Immunohistochemistry for lucifer-
ase conﬁrmed extensive expression throughout the heart with a
mosaic pattern (Figure 1e–h) typical of AAV gene transfer.22 In
conclusion, cardiac expression of IGF-1Ea starting between 3 and
7 days after injection exhibited robust and sustained gene
expression, and bioluminescent imaging of luciferase was a
faithful indicator of co-expressed IGF-1Ea.
AAV9.IGF-1Ea Gene transfer improves global left ventricular
function after ischemia/reperfusion
To test the efﬁcacy of virally delivered IGF-1Ea in ameliorating the
response to cardiac injury, mice underwent myocardial ischemia
for 45 min followed by reperfusion. Four groups of animals
were compared; mice with no viral treatment (ischemia/reperfu-
sion (I/R)) and a group receiving 3.5 × 1011 GC AAV9.GFP (I/R+GFP)
were used as negative-control groups; two different viral titres
groups for AAV9.IGF-1Ea were tested, 3.5 × 1010 GC and 3.5 × 1011
GC (I/R+IGF-1Ea.1010 and I/R+IGF-1Ea.1011), respectively. AAV9
administration was performed 5 h after surgery by intrafemoral
vein injection and mice were killed 28 days after injection
(Figure 2a). A signiﬁcant dose-dependent increase in IGF-1Ea
mRNA levels was observed in those groups that received the
AAV9.IGF-1Ea treatment (Figure 2b). ELISA quantiﬁcation revealed
no differences in IGF-1 serum levels between groups (Figure 2c),
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Figure 1. Time course of AAV9 vector mediated IGF-1Ea gene expression in the murine heart after intravenous injection. (a) Schematic
representation of recombinant AAV vector. The construct contains the mouse IGF-1Ea gene (462 bp) and an internal ribosomal entry site (IRES)
followed by the ﬁreﬂy luciferase reporter gene. The expression of this bi-cistronic DNA is under the control of the cardiac troponin promoter
(cTNT), and the SV40 polyA signal, ﬂanked by inverted terminal repeats (ITR), shown as hairpin loops. The AAV vectors (AAV9.GFP and AAV9.
IGF-1Ea) were packaged into AAV9 capsids. (b) Bioluminecesce imaging of uninjured mice illustrating the distribution of luciferase after AAV9.
IGF-1Ea administration (3.5 × 1011 genome copies). Ex vivo bioluminescence images at indicated times of various tissues (heart, liver, gut,
spleen, kidney and lungs) after IGF-1Ea cardiac gene transfer. Quantitative qPCR analysis of (c) luciferase and (d) IGF-1Ea in the heart at several
timepoints after injection of I/R+IGF1Ea.1011. n= 3. *Po0.05, **Po0.001. One-way ANOVA with Dunnett’s Multiple Comparison test. I/R group
(no viral treatment group) as control group. (e–h) Immunohistochemistry of luciferase expression in heart sections 28 days after I/R in e, f
AAV9.IGF-1Ea 3.5 × 1011 GC injected 5 h after I/R. (e) whole heart and (f) 40 ´ magniﬁcation. (g, h) no virus (I/R) group, (g) whole heart and (e)
× 40 magniﬁcation. (d, e) Scale bar, 1 mm. (e–g) Scale bar, 250 μm. LV, left ventricle; RV, right ventricle. Mean values± s.e.m. are shown.
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conﬁrming, our previous study, that IGF-1Ea strongly adheres into
extracellular matrix, retaining the propeptides locally, preventing
their release into the circulation, and minimising the potential
hazard of ectopic effects.23
Echocardiographic analysis 28 days after I/R revealed improved
left ventricular ejection fraction in mice treated with AAV9.IGF-1Ea
(I/R+IGF1Ea.1010 and I/R+IGF-1Ea.1011) compared with untreated
mice and mice treated with AAV9.GFP (Figure 3a and
Supplementary Table S1). Left ventricular (LV) volume, as measure
of LV dilation, in IGF-1Ea overexpressing mice at 28 days was also
improved compared with LV volume at 3 days in the same group.
In addition, AAV9.IGF-1Ea treated mice showed reduced LV
dilation 28 days post-I/R (Figure 3b,c and Supplementary Table
S1) compared with I/R and I/R+GFP groups. All four groups
showed similar functional worsening in cardiac parameters and
chamber dilation 3 days post-I/R regardless of the treatment,
suggesting that initial infarct size was analogous among all groups
(Supplementary Table S1). Notably, functional improvement was
more evident in those groups where the highest AAV9.IGF-1Ea
viral titre was administered.
Regional left ventricular wall motion is enhanced by 28 days after
AAV9.IGF-1Ea gene transfer
We performed quantitative evaluation of LV regional wall motion
after infarction using echocardiography. Consistent with the LV
functional data, an improvement in the wall score motion index
was observed in those groups that received AAV9.IGF-1Ea
(Figure 3d) and a reduction in the number of segments with
altered motility (Figure 3e). Moreover, mice overexpressing
IGF-1Ea showed fewer akinetic segments compared to I/R and I/
R+GFP control groups (Figure 3g). In support of the functional
data, levels of the heart failure marker Acta1 were signiﬁcantly
reduced with AAV9.IGF-1Ea treatment (Figure 3f). In agreement
with our evidence that initial infarct size was not changed, no
signiﬁcant difference was observed between the different groups
for either wall score motion index or individual segment
assessment at 3 days post-I/R (Supplementary Table S1). Both
the wall score motion index and the contraction assessment
indicate that AAV9.IGF-1Ea treatment improves the overall
contractile function of the heart.
AAV9.IGF-1Ea gene transfer reduces infarct size and cardiac
ﬁbrosis
We performed histological analysis to determine infarct size,
infarct expansion and scar thickness after AAV9.IGF-1Ea treatment.
Improved cardiac function in the AAV9.IGF-1Ea groups was
accompanied by thicker scars when compared with the no viral
treatment (I/R) and I/R+GFP control groups (Figure 4a), along with
a reduction in total heart ﬁbrosis (Figure 4b). Scar length was also
diminished in the IGF-1Ea-treated groups (Figure 4c), suggesting
reduced infarct expansion. Functional and histological ﬁndings
were conﬁrmed at molecular level by monitoring LV ﬁbrosis
markers such as collagen 1 (Col1α1), collagen 3 (Col1α3),
lysyl oxidase (Lox) and Thy1/CD90. Measured 28 days after
IGF-1Ea cardiac gene transfer, the Col1α1/Col1α3 mRNA ratio
was increased in the AAV9.IGF-1Ea groups (Figure 4d and
Supplementary Figure S3A), indicating a difference in extracellular
matrix composition. Higher levels of Lox were detected. Lox acts
as crosslink molecule between collagen and elastin molecules into
mature ﬁbres (Figure 4e) potentially strengthening the scar. As a
measurement of ﬁbroblast proliferation, we quantiﬁed Thy1/CD90
levels, which were increased in the AA9.IGF-1Ea group (Figure 4f).
No changes were observed in the macrophage marker CD68
(Supplementary Figure S3B).
Interestingly, scars of AAV9.IGF-1Ea treated group were
characterised by higher cardiomyocyte content (Figure 4g–j). To
assess the generation of new myocardial tissue in the infarcted
hearts, mice were given BrdU for 28 days to visualise cumulative
DNA synthesis. Consistent with observations in cardiac-speciﬁc
IGF-1Ea transgenic mice,16 the I/R+AAV9.IGF-1Ea.1011 group
moderately increased percentage of BrdU-positive cardiomycytes
at 28 days post-I/R (Figure 5a–c). Phospho-H3 staining, a mitosis
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Figure 2. AAV9.IGF-1Ea gene transfer experimental design. (a) AAV9.IGF-1Ea was administered intravenously, 5 h after Ischemia/Reperfusion
(I/R) and echocardiographic measurements were performed at 3 days and 28 days after I/R. Organs were collected at 28 days for analysis.
(b) IGF-1Ea mRNA levels in the heart 28 days after cardiac gene transfer were quantiﬁed by qRT-PCR. n= 5–12 per group. (c) IGF-1 Serum levels
28 days post-I/R. n= 6–12 per group. *Po0.05, **Po0.001. One-way ANOVA with Dunnett’s Multiple Comparison test. I/R group (no viral
treatment group) as control group. Mean values± s.e.m. are shown.
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marker, did not reveal any signiﬁcant difference between the
groups at 28 days (Supplementary Figure S4), suggesting a lack of
on-going proliferation at that stage. We also assessed whether
IGF-1Ea gene transfer promoted enhanced vascularisation for
proper blood supply to the scars. Indeed, αSMA immunohisto-
chemistry showed an increase in arterioles in the AAV9.IGF-1Ea-
treated groups with the highest titre (Figure 5d–f). Histological
ﬁndings were conﬁrmed by quantifying the mRNA levels of
PECAM-1 (CD31) as marker vascular growth (Figure 5g). The
greatest difference was obtained with the I/R+AAV9.IGF-1Ea.1011
thus the higher viral titre was used in preceding experiments. As
no signiﬁcant differences were observed between the no viral
treatment group (I/R) and the I/R+GFP control groups, only I/R is
presented.
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Figure 3. IGF-1Ea gene transfer improves cardiac function and reduces LV dilation after I/R. (a–c) Animals were analyzed by echocardiography
3 and 28 days post-I/R. (a) LV ejection fraction and (b, c) LV end-systolic and end-diastolic volumes, (d) wall score motion index (WSMI) and (e)
number of segments affected were determined. (f) mRNA levels of α-skeletal actin in the remote myocardium analyzed by qRT-PCR.
(g) Segment analysis based on wall motion and thickening. Segment scores are colored coded from green to red representing: normal or
normal= green, hypokinesis= yellow, akinesis= red. Black bars: 3 days after I/R, white bars: 28 days port I/R. n= 7-13. *Po0.05 I/R versus AAV9.
GFP, AAV9.IGF-1Ea groups. One-way ANOVA with Dunnett's Multiple Comparison post-test. yPo0.05. Two-way ANOVA to compare the 4
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AAV9.IGF-1Ea treatment promotes cardiac Akt-mediated signalling
The main effects of IGF-1 are achieved through the Akt signalling
pathway. In the heart, IGF-1 mediates Akt phosphorylation on the
serine-473 residue, which indicates Akt activation.24 AAV9.IGF-1Ea
treatment increased IGF-1 protein content in the heart by 1.5-fold
when compared with the I/R group. At 28 days post-I/R,
mice treated with AAV9.IGF-1Ea exhibited a 1.7-fold increase
in P-Ser473Akt. Phosphorylation of mTOR, downstream of Akt, was
also increased by 1.8-fold after I/R in the AAV9.IGF-1Ea-treated
groups (Figure 6a,b).
DISCUSSION
In this study, we have demonstrated for the ﬁrst time that a single
intravenous injection of AAV9.IGF-1Ea after ischemic injury
induced improvements in LV cardiac function post-I/R through
partial recovery of LV contraction and quality motion, reducing
total ﬁbrosis and infarct expansion limiting adverse remodelling.
Interestingly, analysis of the main extracellular matrix compo-
nents, collagen 1 and collagen 3, showed a skewing in favour of
collagen synthesis which may confer different mechanical and
physical properties to the infarct. As with previous models of IGF-1
administration, the AAV9 virus was able to induce an increase in
the formation of new capillaries.25 Although the salutary effects of
direct intramyocardial injection of IGF-1 expression vectors has
been previously documented.25–27 This is the ﬁrst report of
sustained effective improvement by virally encoded IGF-1Ea
propeptide in a more therapeutically relevant delivery mode.
Over the years, the use of AAVs in preclinical28–30 and clinical
studies31,32 has positioned AAVs as the vector of choice for cardiac
gene transfer. This is mainly due to the diverse tissue tropism
determined by the capsid serotype, the lack of pathogenicity, low
immunogenicity and robust gene expression achieved with this
system.19 We also show that single administration of the AAV9
virus provided robust and early onset of IGF-1Ea expression in the
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Figure 4. AAV9.IGF-1Ea treatment reduces infarct expansion and myocardial remodelling in AAV9.IGF-1Ea treated mice. (a) Scar thickness,
(b) total ﬁbrosis and (c) scar lenght were analysed 28 days post-I/R using histological methods. (d) Col1α1/Col3α1 ratio, (e) Lox and (f) Thy1
mRNA relative levels were analysed by qRT-PCR. (g–j) Representative masson’s thricome staining of infarct regions from all four groups. (g) I/R
group, (h) I/R+GFP group, (i) I/R+IGF1Ea.1010 and (j) I/R+IGF1Ea.1011. n= 5–12 per group. *Po0.05, **Po0.001. I/R versus all three groups.
One-way ANOVA followed with Dunnett’s post-test. Scale bar, 250 μm. Results are expressed as mean fold induction ± s.e.m. over the values of
uninjured hearts (dashed line).
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heart, with the cTNT promoter proving sufﬁcient to achieve
therapeutic IGF-1Ea transcription after single systemic injection.
AAV9-mediated luciferase gene expression was also detected in
the liver at much lower levels, which overrode the cardiac
speciﬁcity of the cTNT promoter.22,29,33 However, this was not
paralleled by an increase in IGF-1Ea mRNA levels in the liver after
AAV9.IGF-1Ea treatment, indicating that IGF-1Ea overexpression
was cardiac-speciﬁc. Notably, in this study, we show for the ﬁrst
time that the IGF-1Ea propeptide can be successfully delivered
and overexpressed in the heart by Gene Therapy. The Ea moiety in
the IGF-1Ea propeptide, which is efﬁciently cleaved, anchors IGF-1
to the extracellular matrix in other tissues preventing its clearance
and reducing off-target effects.23 This feature dampens the
risks associated with elevated systemic IGF-1 levels such as
hypotension34 and hypoglycaemia.35
We have previously shown that cardiac overexpression of
IGF-1Ea in transgenic mice resulted in repression of the
pro-inﬂammatory cytokines interleukin (IL)-1β and IL-6, while the
anti-inﬂammatory IL-4 and IL-10 showed higher expression levels
when compared with wild-type (WT) animals after cardiotoxin
injury. We found that IGF-1Ea decreased the number of apoptotic
cells at the injured site, which is at least in part attributable to the
induction of UCP-1, metallothionine 2 and the cardioprotective
cytokine adiponectin16 reducing infarct size.
The diverse functions of IGF-1 are mediated through the same
receptor (IGF-1R), which upon activation leads to the recruitment
of other substrates that in turn activate different signal
pathways.36,37 Upon IGF-1R activation, active PI3-kinase phosphor-
ylates inositol phospholipids.38,39 This phosphorylation is required
to induce several downstream targets such as Akt, which
promotes protein synthesis and cell survival, among other
functions. Although BrdU labelling showed increased percentage
of positive cardiomyocites in AAV9.IGF-1Ea-treated group, no
differences were observed with Phospo-H3 staining at 28 days.
IGF-1Ea also induces the expression of the calcineurin splicing
variant CnAβ.40 Interestingly, the effects of AAV9.IGF-1Ea are
reminiscent of those of CnAβ1 overexpression, which results in Akt
activation, improved vascularisation of the infarct region and
reduced infarct expansion leading to reduced remodelling and
improved cardiac function post-infarction.41,42
In summary, this study demonstrates that intravenous delivery
of AAV9.IGF-1Ea is effective in improving post I/R cardiac function,
preventing infarct expansion and dilation. This is attributed to the
combined effects of a cardiotropic gene delivery vehicle, AAV9
and the pleiotropic action of IGF-1Ea in the heart. The escalating
incidence of acute cardiovascular disease leading to heart failure
underscores the increasingly urgent need for improved therapeu-
tic strategies to limit cardiac tissue damage and improve
functional outcomes in translational settings. From a clinical
standpoint, intravenous injection is the least invasive mode of
delivery for cardiac Gene Therapy, although a higher efﬁciency
would be achieved by delivering the AVV9.IGF-1Ea vector by
intracoronary infusion during cardiac catheterisation in patients.
These results provide a rationale to conduct additional studies in
larger animals for translation to clinical application.
MATERIALS AND METHODS
Viral vector plasmids, production and puriﬁcation
Self-complementary adeno-associated plasmid containing the IGF-1Ea
cDNA was generated from a pA-cTNT-Luciferase plasmid kindly provided
by Juan Bernal, CNIC, Madrid, Spain. Mus muculus IGF-1Ea consensus
sequence was cloned into pA-cTNT-Luciferase backbone and construct
integrity was conﬁrmed by sequencing. AAV vectors were produced and
puriﬁed by Penn Vector Core (University of Pennsylvania) as described.43
The vector was subjected to vector genome titrations, sodium dodecyl
sulfate-polyacrylamide gel electrophoresis analysis for particle purity, and
transgene expression analysis in HL-1 cells.
Cardiac injury model
Myocardial infarction was induced by ischemia-reperfusion (I/R) in C57BL/6
male mice, 8 to 12 weeks old, obtained from Charles River. The infarcts
were performed by ligation of the left coronary artery for 45 min followed
by reperfusion of the artery. Surgeries were performed under general
anesthesia with 3–3.5% sevoﬂurane and mechanical ventilation was
provided during the procedure. The mortality rate in the ﬁrst 24 h post-
I/R was 38%; no mortality was found afterwards. Mice received analgesic
treatment with buprenorphine (0.3 mg/kg, subcutaneously) after surgery.
1 mg/ml of bromodeoxyuridine (BrdU), was administered in the water of all
four groups and renewed every 2 days.
In vivo gene transfer
Five hours after I/R, mice were anaesthetised with 1.5–2.5% sevoﬂurane
and 50 μl of concentrated AAV vector (in phosphate-buffered saline) was
injected intravenously through the left femoral vein using a 29-gauge
insulin syringe. AAV9 administration was performed as follows. One group
received 3.5 × 1011 genome copies (GC) of AAV9.GFP as a AAV control. For
the IGF-1Ea gene transfer, two different viral titers were administered,
3.5 × 1010 GC and 3.5 × 1011 GC of AAV9.IGF-1Ea.
Detection of serum IGF-1 protein
The sera from the four groups were utilised for measurements of total
IGF-1 using a commercially available ELISA kit speciﬁc for rodent IGF-1
(Peprotech, London, UK, 900-K170). Calculations of IGF-1 content were
based on a standard curve generated from recombinant mouse IGF-1.
Total rodent IGF-1 was detected according to the manufacturer’s
instruction.
Echocardiographic analysis
Transthoracic echocardiography and analysis was blindly performed at
baseline, 3 and 28 days post-I/R injury in anaesthetised mice to evaluate LV
systolic function, chamber dimensions, wall thickness, infarct size and wall
motion. All measurements were carried out in accordance with the
recommendations for chamber quantiﬁcation from the American Society
of Echocardiography in conjunction with the European Association of
Echocardiography.41,44 Left ventricle wall motion score index was
calculated in order to assess global and regional cardiac function by a
12-based segment model, considering parasternal two-dimensional short
and long axis views at 3 levels (base, middle and apex). In each level, the
left ventricle was divided in 4 segments (anterior, lateral, inferior and
septal) and each segment was scored according its severity in terms of
contraction as 1 (normal), 2 (hypokinetic), 3 (akinetic), 4 (dyskinetic) and 5
(aneurysmal).44 Number of segments affected is calculated as the number
of segments with abnormal contractility out of the 12 segments of the
heart (Score41). Cardiac score is the sum of the severity score of each
segment. The colour-coded heart quantiﬁcation is calculated as the
average score of the same segment (anterior, lateral, inferior and septal
from base, middle and apex) throughout all samples. Wall motion score
index deﬁned as the ratio of the sum of scored individual segment over
the total number of segments evaluated. Infarct size was also estimated
considering the mean of scored individual segments. For this study, 140
mice underwent I/R with a mortality rate of 38%. An exclusion criterion was
pre-established taking into account that both large and small infarct
inﬂuence the outcome depending on which group could randomly be
allocated. Therefore, homogeneous infarct sizes were selected according
to the following exclusion criteria: Only mice that presented two or more
akinetic cardiac segments plus a LV ejection fraction below 45% at 3 days
post-surgery were selected for the study. After applying the exclusion
criteria, mice were randomly allocated to form the four groups. Further
description of the echocardiographic methods can be found in
Supplementary Materials.
Bioluminescence analysis
Mice were anaesthetised with 1.5–2% isoﬂurane in oxygen. D‐luciferin
(Promega, Madison, WI, USA, E1601) at 100 mg/kg in saline was
administered to mice by intraperitoneal injection. 5–10 min after
D‐luciferin administration, all mice were imaged in supine position using
a Xenogen IVIS100 imaging system (Caliper Life Sciences, Hopkinton, MA,
USA). Organs were immersed in D-luciferin for 1 min and bioluminesce was
imaged immediately after using the IVIS 100 system. Photons emitted from
the mice were collected and integrated for 1 min. Images were processed
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using Living Image software (Caliper Life Sciences). Mean luminescence
intensities (photons per s cm2 sr) were measured from the regions of
interest over the mouse hearts.
Histology, immunohistochemistry and immunoﬂuorecesce
Scar length was determined in Masson’s trichrome-stained sections
using the midline method, which best correlates with functional
measurements.45 In this method, the infarct length is measured as the
length of the midline of the infarcted wall, in which 50% of the wall
thickness is composed of scar tissue. Scar length represents the
percentage of infarct length with respect to the length of the whole LV
circumference. Total ﬁbrosis was quantiﬁed by ImageJ (NIH, Bethesda, MD,
USA) in whole heart images obtained at the middle section. Further
description of Masson’s, immunohistochemistry and immunoﬂuorescence
staining can be found in Supplementary Material.
RNA isolation and quantitative reverse-transcriptase PCR
After sacriﬁcing the mice, the hearts were perfused with phosphate-
buffered saline, and samples from the infarct region, border zone and
remote myocardium were harvested and snap-frozen in liquid nitrogen.
Total RNA was isolated using the RNeasy kit from Qiagen, with DNAse
digestion on the column. Quantitative reverse transcription PCR (qRT-PCR)
data were analysed using the LinReg (Amsterdam, Netherlands) software in
order to estimate the efﬁciency rates and the Ct values.46
Western blot
Western blot was performed using the following primary antibodies
anti-phospho-Akt-Ser473 (Cell Signaling, Danvers, MA, USA), anti-Akt
(Cell Signaling), anti-phospho mTOR- Ser 2448 (Cell Signaling), anti-
mammalian target of rapamycin (mTOR; Cell Signaling), IGF-1 (Sigma,
Dorset, UK) and α-Tubulin (Sigma) as previously described.47,48 Brightness
and contrast were linearly adjusted using power point.
Statistics
Data are presented as mean± s.e.m. In addition, a two-way analysis of
variance (ANOVA) with repeated measures followed by Bonferroni post-
test was applied to compare mice at 3 versus 28 days post-I/R. Group
differences in qRT-PCR and histological quantiﬁcations were analysed by
one-way ANOVA followed by Dunnett’s post-test to compare with
untreated mice. Student’s t-test or two-way ANOVA, followed by
Bonferroni’s post-test was performed to quantify vessels and western blot
analysis. G*Power 3.1 (Heinrich-Heine-Universität Düsseldorf, http://www.
gpower.hhu.de) software was used to estimate sample size of each group
after surgery with a 95% conﬁdence level and 5% margin of error. Data
were analysed with GraphPad-Prism 5.0 (Graphpad Software, www.
graphpad.com), and differences were considered statistically signiﬁcant
at Po0.05. Further description of the statistical analysis can be found in
Supplementary Material.
ACKNOWLEDGEMENTS
We are grateful to E.L.P.'s group at the CNIC for excellent technical assistance
and advice, and to members of the Rosenthal laboratory for critical discussion.
We also thank the University of Pennsylvania, Penn Vector Core, for generating
AAV9 vectors. This work was supported by grants from the European Unionś
Seventh Framework Programme Marie Curie Initial Training Network—CardioNeT
GA-289600 to N.R. and E.L.P., and British Heart Foundation grants—RM/13/1/30157
to N.R. E.L.P. was also supported by European Unionś Seventh
Framework Programme -CardioNext ITN-608027, CardioNeT-ITN-289600), from the
Spanish Ministry of Economy and Competitiveness (SAF2012–31451) and from the
Regional Government of Madrid (2010-BMD-2321 ‘Fibroteam’). E.G.C. gratefully
acknowledges the support from the BritishSpanish Society (BSS) for the British-
Spanish Society/Santander Universities 2015 fellowship that partially supported this
project.
CONTRIBUTIONS
Authorship of this manuscript follows the ICMJE criteria.
COMPETING INTERESTS
The authors declare no conﬂict of interest.
REFERENCES
1. Go, A. S. et al. Heart disease and stroke statistics-2014 update: a report from the
American Heart Association. Circulation 129, e28–e292 (2014).
2. Lee, D. S. et al. A systematic assessment of causes of death after heart failure
onset in the community: impact of age at death, time period, and left ventricular
systolic dysfunction. Circ. Heart Fail. 4, 36–43 (2011).
3. Yancy, C. W. et al. 2013 ACCF/AHA guideline for the management of heart failure:
A report of the american college of cardiology foundation/american heart
association task force on practice guidelines. Circulation 128, 240–327 (2013).
4. Deb, S. et al. Coronary artery bypass graft surgery versus percutaneous inter-
ventions in coronary revascularization. JAMA 310, 2086 (2013).
5. Zweier, J. L. Measurement of superoxide-derived free radicals in the reperfused
heart. Evidence for a free radical mechanism of reperfusion injury. J. Biol. Chem.
263, 1353–1357 (1988).
6. Rotwein, P., Pollock, K. M., Didier, D. K. & Krivi, G. G. Organization and sequence of
the human insulin-like growth factor I gene. Alternative RNA processing
produces two insulin-like growth factor I precursor peptides. J. Biol. Chem. 261,
4828–4832 (1986).
7. Frindik, J. P. & Kemp, S. F. Managing idiopathic short stature: role of somatropin
(rDNA origin) for injection. Biologics 4, 147–155 (2010).
8. Laron, Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol. Pathol. 54,
311–316 (2001).
9. D’Ercole, A. J., Stiles, A. D. & Underwood, L. E. Tissue concentrations of somato-
medin C: further evidence for multiple sites of synthesis and paracrine or
autocrine mechanisms of action. Proc. Natl Acad. Sci. USA 81, 935–939 (1984).
10. Musarò, a. et al. Localized Igf-1 transgene expression sustains hypertrophy and
regeneration in senescent skeletal muscle. Nat. Genet. 27, 195–200 (2001).
11. Hill, M. & Goldspink, G. Expression and splicing of the insulin-like growth factor
gene in rodent muscle is associated with muscle satellite (stem) cell activation
following local tissue damage. J. Physiol. 549, 409–418 (2003).
12. Barton-Davis, E. R., Shoturma, D. I., Musaro, A., Rosenthal, N. & Sweeney, H. L. Viral
mediated expression of insulin-like growth factor I blocks the aging-related loss
of skeletal muscle function. Proc. Natl Acad. Sci. USA 95, 15603–15607 (1998).
13. Pelosi, L. et al. Local expression of IGF-1 accelerates muscle regeneration by
rapidly modulating inﬂammatory cytokines and chemokines. FASEB J. 21,
1393–1402 (2007).
14. Tonkin, J. et al.Monocyte/macrophage-derived IGF-1 orchestrates murine skeletal
muscle regeneration and modulates autocrine polarization. Mol. Ther. 23,
1189–1200 (2015).
15. Gallego-Colon, E. et al. Cardiac-restricted IGF-1Ea overexpression reduces the
early accumulation of inﬂammatory myeloid cells and mediates expression of
extracellular matrix remodeling genes after myocardial infarction. Madiat.
Inﬂamm. 2015, 484357 (2015).
16. Santini, M. P. et al. Enhancing repair of the mammalian heart. Circ. Res. 100,
1732–1740 (2007).
17. Gregorevic, P. et al. Systemic delivery of genes to striated muscles using adeno-
associated viral vectors. Nat. Med. 10, 828–834 (2004).
18. Wang, Z. et al. Adeno-associated virus serotype 8 efﬁciently delivers genes to
muscle and heart. Nat. Biotechnol. 23, 321–328 (2005).
19. Weitzman, M. D. & Linden, R. M. Adeno-associated virus biology. Methods Mol.
Biol. 807, 1–23 (2011).
20. Pacak, C. a. et al. Recombinant adeno-associated virus serotype 9 leads to
preferential cardiac transduction in vivo. Circ. Res. 99, e3–e9 (2006).
21. Bostick, B., Ghosh, A., Yue, Y., Long, C. & Duan, D. Systemic AAV-9 transduction in
mice is inﬂuenced by animal age but not by the route of administration. Gene
Ther. 14, 1605–1609 (2007).
22. Prasad, K.-M. R., Xu, Y., Yang, Z., Acton, S. T. & French, B. A. Robust cardiomyocyte-
speciﬁc gene expression following systemic injection of AAV: in vivo gene
delivery follows a Poisson distribution. Gene Ther. 18, 43–52 (2011).
23. Hede, M. S. et al. E-peptides control bioavailability of IGF-1. PLoS ONE 7,
e51152 (2012).
24. Vinciguerra, M. et al. mIGF-1/JNK1/SirT1 signaling confers protection against
oxidative stress in the heart. Aging Cell 11, 139–149 (2012).
25. Dobrucki, L. W. et al. Analysis of angiogenesis induced by local IGF-1 expression
after myocardial infarction using microSPECT-CT imaging. J. Mol. Cell Cardiol. 48,
1071–1079 (2010).
26. Davis, M. E. et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery
with biotinylated peptide nanoﬁbers improves cell therapy for myocardial
infarction. Proc. Natl Acad. Sci. USA 103, 8155–8160 (2006).
AAV9.IGF-1Ea cardiac gene therapy
E Gallego-Colon et al
8
npj Regenerative Medicine (2016) 16001 Published in partnership with the Australian Regenerative Medicine Institute
27. Khan, R. S. et al. Targeting extracellular DNA to deliver IGF-1 to the injured heart.
Sci. Rep. 4, 4257 (2014).
28. Konishi, M., Kawamoto, K., Izumikawa, M., Kuriyama, H. & Yamashita, T. Gene
transfer into guinea pig cochlea using adeno-associated virus vectors. J. Gene
Med. 10, 610–618 (2008).
29. Kaspar, B. K. et al. Myocardial gene transfer and long-term expression
following intracoronary delivery of adeno-associated virus. J. Gene Med. 7,
316–324 (2005).
30. Müller, O. J. et al. Improved cardiac gene transfer by transcriptional and trans-
ductional targeting of adeno-associated viral vectors. Cardiovasc. Res. 70,
70–78 (2006).
31. Zacchigna, S., Zentilin, L. & Giacca, M. Adeno-associated virus vectors as ther-
apeutic and investigational tools in the cardiovascular system. Circ. Res. 114,
1827–1846 (2014).
32. Chacon-Camacho, O. F. Review and update on the molecular basis of Leber
congenital amaurosis. World J. Clin. Cases 3, 112 (2015).
33. Fang, H. et al. Comparison of adeno-associated virus serotypes and
delivery for cardiac gene transfer. Hum. Gene Ther. Methods 23, 234–241
(2013).
34. Cheng, P.-W. et al. Involvement of two distinct signalling pathways in
IGF-1-mediated central control of hypotensive effects in normotensive and
hypertensive rats. Acta Physiol. 212, 28–38 (2014).
35. Kovacs, G. T. et al. Hypoglycemic effects of insulin-like growth factor-1 in
experimental uremia: Can concomitant growth hormone administration prevent
this effect? Horm. Res. 51, 193–200 (1999).
36. Butler, A. A. et al. Insulin-like growth factor-I receptor signal transduction: at the
interface between physiology and cell biology. Comp. Biochem. Physiol.
B Biochem. Mol. Biol. 121, p 19–26 (1998).
37. Coolican, S. A., Samuel, D. S., Ewton, D. Z., McWade, F. J. & Florini, J. R. The
mitogenic and myogenic actions of insulin-like growth factors utilize distinct
signaling pathways. J. Biol. Chem. 272, 6653–6662 (1997).
38. Fujio, Y., Nguyen, T., Wencker, D., Kitsis, R. N. & Walsh, K. Akt promotes survival of
cardiomyocytes in vitro and protects against ischemia-reperfusion injury in
mouse heart. Circulation 101, 660–667 (2000).
39. Rommel, C. et al. Mediation of IGF-1-induced skeletal myotube hypertrophy
by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3,
1009–1013 (2001).
40. Lara-Pezzi, E. et al. A naturally occurring calcineurin variant inhibits FoxO activity
and enhances skeletal muscle regeneration. J. Cell Biol. 179, 1205–1218 (2007).
41. López-Olañeta, M. M. et al. Induction of the calcineurin variant CnAβ1 after
myocardial infarction reduces post-infarction ventricular remodelling by
promoting infarct vascularization. Cardiovasc. Res. 102, 396–406 (2014).
42. Santini, M. P. et al. IGF-1Ea induces vessel formation after injury and mediates
bone marrow and heart cross-talk through the expression of speciﬁc cytokines.
Biochem. Biophys. Res. Commun. 410, 201–207 (2011).
43. Gao, G. et al. Biology of AAV serotype vectors in liver-directed gene transfer to
nonhuman primates. Mol. Ther. 13, 77–87 (2006).
44. Lang, R. M. et al. Recommendations for chamber quantiﬁcation: A report from the
American Society of Echocardiography’s guidelines and standards committee
and the Chamber Quantiﬁcation Writing Group, developed in conjunction with
the European Association of Echocardiograph. J. Am. Soc. Echocardiogr. 18,
1440–1463 (2005).
45. Takagawa, J. et al. Myocardial infarct size measurement in the mouse chronic
infarction model: comparison of area- and length-based approaches. J. Appl.
Physiol. 102, 2104–2111 (2007).
46. Ruijter, J. M. et al. Ampliﬁcation efﬁciency: linking baseline and bias in the
analysis of quantitative PCR data. Nucleic Acids Res. 37, e45 (2009).
47. Blackstock, C. D. et al. Insulin-like growth factor-1 increases synthesis of collagen
type I via induction of the mRNA-binding protein LARP6 expression and binding
to the 5’stem-loop of COL1a1 and COL1a2 mRNA. J. Biol. Chem. 289,
7264–7274 (2014).
48. Panse, K. D. et al. Follistatin-like 3 mediates paracrine ﬁbroblast activation by
cardiomyocytes. J. Cardiovasc. Transl. Res. 5, 814–826 (2012).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
© The Author(s) 2016
Supplementary Information accompanies the paper on the npj Regenerative Medicine website (http://www.nature.com/npjregenmed)
AAV9.IGF-1Ea cardiac gene therapy
E Gallego-Colon et al
9
Published in partnership with the Australian Regenerative Medicine Institute npj Regenerative Medicine (2016) 16001
